Wentworth Kerry 4

What Happened
Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio (NUVB), exercised multiple stock option lots and sold 200,000 shares in an open-market transaction on April 6, 2026. The filing shows exercises/conversions of four 100,000-share option blocks: two were reported as acquired (100,000 shares @ $1.87; $187,000 and 100,000 shares @ $1.94; $194,000 — total cash paid $381,000) and two 100,000-share blocks were reported as disposed at $0.00 (likely shares surrendered/withheld). Separately, 200,000 shares were sold in the open market at a weighted-average price of $4.52 for gross proceeds of $903,560.

Key Details

• Transaction date: April 6, 2026 (Form 4 filed April 8, 2026). Filing appears within the typical two-business-day Form 4 window.
• Sales: 200,000 shares sold in open market; weighted-average sale price $4.52 (range $4.44–$4.64); proceeds reported $903,560. (F2: detailed per-price breakdown available upon request.)
• Exercises/conversions: four derivative entries of 100,000 shares each — two acquired (strikes $1.87 and $1.94) and two disposed at $0.00 (derivative disposition).
• Shares owned after transaction: not specified in the supplied excerpt of the filing.
• Notable footnotes: sales were made pursuant to a 10b5-1 plan dated Dec 4, 2025 (F1). Vesting schedules for the option grants are noted (F3, F4).
• No late-filing flag provided in the excerpt.

Context
The combination of option exercises and immediate open-market sales often reflects routine liquidity actions or planned sales rather than an unsolicited market opinion. The two derivative dispositions at $0.00 typically indicate shares were surrendered or withheld (for taxes or to satisfy option exercise requirements) rather than a separate cash sale. The open-market sales occurred under a pre-established 10b5-1 plan, which is a prearranged trading program that can authorize sales regardless of short-term company developments.